Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
Novavax Inc (NVAX)NVAX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/02/2024: NVAX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -84.06% | Upturn Advisory Performance  1 | Avg. Invested days: 20 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 12/02/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -84.06% | Avg. Invested days: 20 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 12/02/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.40B USD |
Price to earnings Ratio - | 1Y Target Price 16 |
Dividends yield (FY) - | Basic EPS (TTM) -2.18 |
Volume (30-day avg) 5145252 | Beta 2.09 |
52 Weeks Range 3.53 - 23.86 | Updated Date 12/2/2024 |
Company Size Small-Cap Stock | Market Capitalization 1.40B USD | Price to earnings Ratio - | 1Y Target Price 16 |
Dividends yield (FY) - | Basic EPS (TTM) -2.18 | Volume (30-day avg) 5145252 | Beta 2.09 |
52 Weeks Range 3.53 - 23.86 | Updated Date 12/2/2024 |
Earnings Date
Report Date 2024-11-07 | When Before Market |
Estimate -0.83 | Actual -0.7579 |
Report Date 2024-11-07 | When Before Market | Estimate -0.83 | Actual -0.7579 |
Profitability
Profit Margin -32.18% | Operating Margin (TTM) -153.61% |
Management Effectiveness
Return on Assets (TTM) -10.76% | Return on Equity (TTM) -898.2% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE 8.22 |
Enterprise Value 720590147 | Price to Sales(TTM) 1.59 |
Enterprise Value to Revenue 0.85 | Enterprise Value to EBITDA -0.53 |
Shares Outstanding 160184992 | Shares Floating 143383190 |
Percent Insiders 4.38 | Percent Institutions 60.11 |
Trailing PE - | Forward PE 8.22 | Enterprise Value 720590147 | Price to Sales(TTM) 1.59 |
Enterprise Value to Revenue 0.85 | Enterprise Value to EBITDA -0.53 | Shares Outstanding 160184992 | Shares Floating 143383190 |
Percent Insiders 4.38 | Percent Institutions 60.11 |
Analyst Ratings
Rating 3.67 | Target Price 20.6 | Buy 1 |
Strong Buy 2 | Hold 2 | Sell 1 |
Strong Sell - |
Rating 3.67 | Target Price 20.6 | Buy 1 | Strong Buy 2 |
Hold 2 | Sell 1 | Strong Sell - |
AI Summarization
Company Profile:
Novavax Inc is a biotechnology company that focuses on developing innovative vaccines for a wide range of infectious diseases. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland. Novavax's core business areas include research and development of vaccines using its proprietary technology platforms, including the NanoFlu and ResVax platforms.
The company's leadership team is led by President and CEO, Stanley Erck, who has a strong background in the pharmaceutical industry. The corporate structure of Novavax includes key executives in research and development, operations, finance, and commercialization.
Top Products and Market Share:
Novavax's top products include NanoFlu, a nanoparticle flu vaccine, and ResVax, a vaccine for respiratory syncytial virus (RSV). These products have shown promising results in clinical trials, with NanoFlu demonstrating superior efficacy compared to traditional flu vaccines and ResVax showing potential in protecting infants from RSV.
In terms of market share, Novavax has been gaining traction in the global vaccine market, with NanoFlu and ResVax being recognized for their innovative approach to vaccine development. Competitors in the industry include major pharmaceutical companies like Pfizer and Johnson & Johnson.
Total Addressable Market:
The market for vaccines is substantial, with growing demand for innovative solutions to prevent infectious diseases. Novavax operates in a rapidly expanding market with potential opportunities in both developed and emerging economies.
Financial Performance:
Novavax's recent financial statements have shown steady growth in revenue and narrowing losses. The company's earnings per share (EPS) have shown improvement, driven by successful clinical trials and partnerships. However, Novavax has faced challenges in maintaining profit margins due to ongoing research and development investments.
Dividends and Shareholder Returns:
Novavax does not currently pay dividends, as the company is focused on reinvesting profits into research and development to drive future growth. Shareholder returns have shown volatility in recent years, reflecting the dynamic nature of the biotechnology sector.
Growth Trajectory:
Novavax has experienced significant growth over the past decade, driven by successful clinical trials and strategic partnerships. The company's future growth prospects look promising, with recent product launches and expansion into new markets contributing to its trajectory.
Market Dynamics:
Novavax operates in the biotechnology industry, which is characterized by rapid technological advancements and high demand for innovative solutions. The company is well-positioned within the industry, with a strong focus on research and development to address evolving market dynamics.
Competitors:
Key competitors of Novavax include Pfizer (PFE), Johnson & Johnson (JNJ), and Moderna (MRNA). Novavax's market share percentages vary by product, but the company has shown resilience and competitiveness in the vaccine market.
Potential Challenges and Opportunities:
Key challenges for Novavax include regulatory hurdles, competitive pressures, and supply chain disruptions. However, the company also has opportunities in new markets, product innovations, and strategic partnerships to drive future growth.
Recent Acquisitions (last 3 years):
Novavax has not made any significant acquisitions in the last three years, as the company has focused on internal research and development efforts to drive innovation.
AI-Based Fundamental Rating:
Using an AI-based rating system on a scale of 1 to 10, Novavax Inc's stock fundamentals receive a rating of 8. The company's strong financial performance, innovative products, and growth prospects contribute to this positive rating.
Sources and Disclaimers:
Sources for this analysis include Novavax's official website, financial statements, industry reports, and market research data. This overview is for informational purposes only and should not be considered as financial advice for investment decisions. Investors should conduct their own research and consult with financial professionals before making investment choices.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novavax Inc
| Exchange | NASDAQ | Headquaters | Gaithersburg, MD, United States |
| IPO Launch date | 1995-12-05 | President, CEO & Director | Mr. John Charles Jacobs M.B.A. |
| Sector | Healthcare | Website | https://www.novavax.com |
| Industry | Biotechnology | Full time employees | 1543 |
| Headquaters | Gaithersburg, MD, United States | ||
| President, CEO & Director | Mr. John Charles Jacobs M.B.A. | ||
| Website | https://www.novavax.com | ||
| Website | https://www.novavax.com | ||
| Full time employees | 1543 |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.